Fatal pulmonary haemorrhage with the combined use of abciximab and fibrinolytic agent

Singapore Med J. 2002 Nov;43(11):587-9.

Abstract

The increased bleeding risk associated with the use of abciximab has been well reported. The risk appears to be amplified when abciximab is administered concurrently with a fibrinolytic agent. We report and review the literature on the occurrence of a case of fatal pulmonary haemorrhage, a rare bleeding complication, in a patient who received both these drugs.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Abciximab
  • Antibodies, Monoclonal / adverse effects*
  • Drug Therapy, Combination
  • Fatal Outcome
  • Fibrinolytic Agents / adverse effects*
  • Hemorrhage / chemically induced*
  • Humans
  • Immunoglobulin Fab Fragments / adverse effects*
  • Lung Diseases / chemically induced*
  • Male
  • Middle Aged
  • Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors
  • Streptokinase / adverse effects*

Substances

  • Antibodies, Monoclonal
  • Fibrinolytic Agents
  • Immunoglobulin Fab Fragments
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Streptokinase
  • Abciximab